Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospec
- PDF / 984,123 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 63 Downloads / 192 Views
Journal of Translational Medicine Open Access
RESEARCH
Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study Yan Zhang1, Jing‑Lu Jin1, Ye‑Xuan Cao1, Hui‑Hui Liu1, Hui‑Wen Zhang1, Yuan‑Lin Guo1, Na‑Qiong Wu1, Ying Gao1, Qi Hua2, Yan‑Fang Li3, Rui‑Xia Xu1, Chuan‑Jue Cui1, Geng Liu1, Qian Dong1, Jing Sun1 and Jian‑Jun Li1*
Abstract Background: Elevated lipoprotein(a) [Lp(a)] and fibrinogen (Fib) are both associated with coronary artery disease (CAD). The atherogenicity of Lp(a) can be partly due to the potentially antifibrinolytic categories. We hypothesize that patients with higher Lp(a) and Fib may have worse outcomes. Methods: In this prospective study, we consecutively enrolled 8,417 Chinese patients with stable CAD from March 2011 to March 2017. All subjects were divided into 9 groups according to Lp(a) (Lp(a)-Low, Lp(a)-Medium, Lp(a)-High) and Fib levels (Fib-Low, Fib-Medium, Fib-High) and followed up for CVEs, including nonfatal acute myocardial infarc‑ tion, stroke, and cardiovascular mortality. Kaplan–Meier, Cox regression and C-statistic analyses were performed. Results: During a median of 37.1 months’ follow-up, 395 (4.7%) CVEs occurred. The occurrence of CVEs increased by Lp(a) (3.5 vs. 5.3 vs. 5.6%, p = 0.001) and Fib (4.0 vs. 4.4 vs. 6.1%, p
Data Loading...
